Poster Session Q - Pathological and Oncological Sciences 2.
Dr. Szepesi, Gabriella
D11TNL
HCEMM-SU Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research
+36702815057
szepesi.gabriella@stud.semmelweis.hu
Assessment Of Acute Cellular Rejection and Quilty Lesions In Formalin-Fixed, Paraffin Embedded Human Cardiac Allograft Biopsies with Proteomic Analysis Using Nanostring GeoMx Digital Spatial Profiler
Gabriella Szepesi1, Beáta Nagy1, Bence Bátai2, Luca Varga1, Stefánia Gróf1, Tímea Teszák3, Balázs Sax3, Csaba Bödör1, Attila Fintha1
1: HCEMM-SU Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2: HCEMM-SU Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary
3: Heart and Vascular Center, Semmelweis University, Budapest, Hungary
Poszter
Poster Session Q - Pathological and Oncological Sciences 2.
Hungarian
Pathological and Oncological Sciences
Introduction
Endomyocardial biopsy (EMB) is the gold standard method in monitoring cardiac allograft rejection after heart transplant. Quilty lesions represent the most problematic lesion to differentiate from rejection in pathological assessment, as it is characterized by the subendocardial accumulation of B- and T-lymphocytes accompanied by follicular dendritic cells and may extend into the underlying myocardium.
Aims
We sought to examine the diagnostic and prognostic significance of proteomics in heart transplant patients with acute cellular rejection (ACR) and Quilty lesions.
Method
Thirty-three FFPE EMB samples from 26 patients who underwent heart transplant were enrolled in the study with 132 regions of interest (ROIs) selected and examined, respectively. The posttransplant EMB samples were analyzed using the NanoString GeoMx (NanoString Technologies, Seattle, WA) pre-defined Immuno-Oncology Protein Panels (Immune Cell Profiling Core, Immune Activation Status, Immune Cell Typing) containing 39 proteins in total. Cardiac allograft rejection was observed in 17 patients (median time until rejection: 20 days, range: 5-385 days) with 2 patients used as negative controls.
Results
A total of 12 protein markers were expressed across all 132 ROIs. CD163 exhibited a 5.09-fold (p=5.55E-09) increase in expression in ACR2 compared to ACR1, a 7.48-fold (p=4.40E-14) increase compared to the Quilty region, and a 6.72-fold (p=1.04E-05) increase compared to the invasive Quilty region. CD34 expression showed a 4,48-fold (p= 5,01E-24) increase in ACR1 compared to Quilty, and a 2,38-fold(p=4,94E-04) increase compared to invasive Quilty and a 2,01-fold (p=7,67E-09) overexpression compared to ACR2. No protein markers were found to be significantly overexpressed in Quilty lesions. CD163 showed a significantly (p=1,7032E-4) higher expression in subgroup ACR2 patients who developed allograft rejection within 30 days after transplantation.
Conclusion
Based on our pilot study, CD163 and CD34 may emerge as potential biomarkers in ACR2 and ACR1 in patients after cardiac transplant, respectively. CD163 may also serve as predictor of early rejection. These preliminary findings warrant further validation.
Semmelweis University
Attila Fintha
I do not give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
poszter
nem rendelkezett róla
7984
16:25
16:28